Login / Signup

Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients.

Reine KanaanCesar YaghiCarole Saade RiachyAnders SchlosserAline HamadeUffe HolmskovMyrna Medlej-HashimGrith Lykke SorensenRania Jounblat
Published in: JGH open : an open access journal of gastroenterology and hepatology (2023)
This study suggests the use of MFAP4 as a potential diagnostic noninvasive biomarker for cirrhosis screening in NAFLD patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • peritoneal dialysis
  • patient reported outcomes
  • human health